-
Mashup Score: 0
Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Pembrolizumab Plus Cabozantinib Improves ORR in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - 1 year(s) ago
A doublet regimen comprised of pembrolizumab and cabozantinib elicited encouraging responses in patients with recurrent metastatic head and neck squamous cell carcinoma, meeting the primary end point of a phase 2 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Pembrolizumab Plus Cabozantinib Improves ORR in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - 1 year(s) ago
A doublet regimen comprised of pembrolizumab and cabozantinib elicited encouraging responses in patients with recurrent metastatic head and neck squamous cell carcinoma, meeting the primary end point of a phase 2 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Pembrolizumab/Cabozantinib Combo Shows Promising Clinical Benefit in Recurrent Metastatic HNSCC - 1 year(s) ago
Nabil F. Saba, MD, FACP, expanded on efficacy data from a phase 2 trial investigating pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma and current challenges and safety concerns in selecting patients for evaluation.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0GPRC5D Antigen–Targeted CAR T-cell Therapy Induces Strong Response in Resistant Multiple Myeloma - 2 year(s) ago
MCARH109, a CAR T-cell therapy targeting the “enigmatic” GPRC5D antigen, generated remissions in 70.6% of patients with relapsed/refractory multiple myeloma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Pafolacianine used during ovarian cancer surgery identified additional tumors that were not detected with conventional means and not otherwise planned for resection, according to results from a phase 3 study recently published in the Journal of Clinical Oncology.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Investigators Validate Role of Liquid Biopsy in Predicting Chromosomal Abnormalities in Myeloid Neoplasms - 2 year(s) ago
Liquid biopsy using targeted next-generation sequencing for early diagnosis and monitoring of patients with myeloid neoplasms is effective and detects chromosomal structural abnormalities.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the use of neoadjuvant mFOLFIRINOX in patients with borderline resectable pancreatic cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the use of neoadjuvant mFOLFIRINOX in patients with borderline resectable pancreatic cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the use of neoadjuvant mFOLFIRINOX in patients with borderline resectable pancreatic cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations. @AndrewPecoraMD @HMHNewJersey #mmsm #OncClub https://t.co/uoqctaUz92 https://t.co/5otmPgjj2v